PROCEPT BioRobotics trades at 2.9x forward EV/2026E revenue, a deep discount to peers, despite 27-33% guided revenue growth. Learn why PRCT stock is a buy.
PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is one of the best pure-play robotics stocks to buy now. PROCEPT BioRobotics Corp. (NASDAQ:PRCT) is among the best pure-play robotics stocks to buy now. The ...
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, ...
The demand for robotics and automation continues to grow, particularly following the pandemic. As labor costs have escalated, companies have invested in labor-saving measures. Market forecasts project ...
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT) (“PROCEPT”), a surgical robotics company whose mission is to revolutionize BPH treatment ...
PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...
Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results